GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

(HealthDay News) — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented ...

Preoperative glucagon-like peptide-1 receptor agonist use is not associated with short-term postoperative aspiration pneumonia.

Discontinuation was defined as 60 days without any GLP-1 RA on hand. Reinitiation was defined as the first fill of any GLP-1 RA after discontinuation. Patients were followed for up to two years ...

No significant difference seen in odds of postoperative pneumonia between adult GLP-1 receptor agonist users and nonusers.

Three studies attempting to tease out the potential effects of glucagon-like peptide 1 receptor agonists (GLP-1 RA) taken before or during pregnancy were presented at the annual meeting of the ...

They matched each GLP-1 RA user with a kidney transplant recipient who had not started a GLP-1 RA, was alive with a functioning graft, and had accrued identical posttransplant survival time.

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.